...
首页> 外文期刊>Drug delivery. >Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium.
【24h】

Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium.

机译:头孢曲松钠的PEG化微观脂质球递送系统的配制和体外评估。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to formulate and evaluate in vitro, ceftriaxone sodium lipospheres dispersions for oral administration. Ceftriaxone sodium lipospheres were prepared by melt-emulsification using 30%w/w Phospholipon 90H in Softisan 154 as the lipid matrix containing increasing quantities of PEG 4000 (10, 20, 30, and 40%w/w). Characterization based on particle size, particle morphology, encapsulation efficiency, loading capacity and pH were carried out on the lipospheres. Microbiological studies of the ceftriaxone sodium-loaded lipospheres were performed using Escherichia coli as the model organism. In vitro permeation of ceftriaxone sodium from the lipospheres through artificial membrane (0.22 microm pore size) was carried out using Franz cell and simulated intestinal fluid (SIF) without pancreatin as acceptor medium. Photomicrographs revealed spherical particles within a micrometer range with minimal growth after 1 month (Maximum size = 64.76 +/- 3.81 microm). Microbiological studies indicated that lipospheres formulated with 20%w/w of PEG 4000 containing 2%w/w or 3%w/w of ceftriaxone sodium gave significantly (p < 0.05) higher inhibition zone diameter than those with 30%w/w or 40%w/w of PEG 4000. The result also indicated that lipospheres with 10%w/w PEG 4000 resulted in significantly higher encapsulation efficiency (p < 0.05) while those with 30%w/w gave the least, while the loading capacity values ranged from 3.22 mg of ceftriaxone sodium/100 mg of lipid to 6.36 mg of ceftriaxone sodium/100 mg of lipid. Permeation coefficient values varied and ranged from 8.55 x 10(-7) cm/s to 2.08 x 10(-6) cm/s depending on the concentration of PEG 4000. The result of this study gave insight that the issue of ceftriaxone stability in oral formulation could be adequately addressed by tactical engineering of lipid drug delivery systems such as lipospheres.
机译:这项研究的目的是配制和评估用于口服的体外头孢曲松钠脂球分散液。头孢曲松钠脂球是通过在Softisan 154中使用30%w / w的Phospholipon 90H作为含有增加量的PEG 4000(10、20、30和40%w / w)的脂质基质的熔融乳化法制备的。在脂球上进行了基于粒径,粒径形态,包封效率,负载量和pH的表征。使用大肠杆菌作为模型生物对头孢曲松钠载脂球进行了微生物学研究。使用Franz细胞和不含胰酶作为受体介质的模拟肠液(SIF),通过人工膜(孔径为0.22微米)从头孢曲松钠脂质体体外渗透。显微照片显示球形颗粒在微米范围内,在1个月后生长最小(最大尺寸= 64.76 +/- 3.81微米)。微生物学研究表明,以20%w / w的PEG 4000配制的脂球包含2%w / w或3%w / w的头孢曲松钠,与使用30%w / w或30%w / w的脂质体相比,抑菌圈直径显着提高(p <0.05)。 PEG 4000的40%w / w。结果还表明,含有PEG 4000的10%w / w的脂球具有显着更高的包封效率(p <0.05),而含有30%w / w的脂质球的包囊效率最低,而负载能力值范围从3.22 mg头孢曲松钠/ 100 mg脂质到6.36 mg头孢曲松钠/ 100 mg脂质。渗透系数值的变化范围从8.55 x 10(-7)cm / s到2.08 x 10(-6)cm / s,具体取决于PEG 4000的浓​​度。这项研究的结果使人深刻认识到头孢曲松酮在体内的稳定性问题。口服制剂可以通过脂质药物输送系统(例如脂质球)的战术工程来适当解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号